Zydus Lifesciences Ltd.

Cadila Healthcare has reported results for the quarter ended September 30, 2011.

The company‘s net profit for Q2FY12 has registered 27.19% growth at Rs 230.98 million  as compared to Rs 181.60 crore forQ2FY11. The company’s total income has increased by 21.23% at Rs 924.61 crore for the second quarter of current fiscal from Rs 762.71 crore for the corresponding quarter of the previous fiscal.

On consolidated basis, group’s net profit for the quarter under review has declined by 39.90% at Rs 102.68 crore for the quarter ended September 30, 2011 as compared to Rs 170.84 crore for the quarter ended September 30, 2010. Group’s total income has increased by 11.332% to Rs 1247.44 crore for the quarter ended September 30, 2011 from Rs 1120.54 crore for the similar quarter of the year 2010.

Hit by rising expenses and interest costs, billion-dollar drug firm Cadila Healthcare reported 40% drop in its consolidated net profit for the second quarter ended September 30, 2011. This has come much below average estimates of analysts covering the company who were expecting Cadila to report Rs 195 crore as profit for the July-September quarter.

Cadila Healthcare’s interest and finance charges amounted to nearly Rs 77 crore in the second quarter as compared to just Rs 16 crore in the same quarter last year. The loan and advances of the company stood at Rs 528.8 crore while its cash and bank balances stood at Rs 605.7 crore at the end of September 30.